IDEXX Labs Acquires RADIL Reference Laboratory

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced today that it has acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri.  IDEXX paid the the University of Missouri $43 million dollars in cash for the research and diagnostic business.

RADIL provides health monitoring and diagnostic testing services to bioresearch customers according to the company.

IDEXX released the following statement regarding the purchase, “The bioresearch market is an excellent strategic fit for IDEXX, allowing us to leverage our expertise in veterinary diagnostics, as well as our integrated offering of reference laboratory and in-clinic testing solutions,” commented Jonathan Ayers, Chairman and Chief Executive Officer. “The acquisition of RADIL, with its international reputation, track record of innovation, and solid relationships with key bioresearch customers, will create a strong foundation for our further participation in this market.”

RADIL provides the biomedical research community with veterinary laboratory diagnostics including serology, pathology, molecular diagnostics, microbiology, and parasitology according to the company, which also said that all RADIL employees will join IDEXX and continue operations in Columbia.

RADIL serves the biomedical research community with veterinary laboratory diagnostics including serology, pathology, molecular diagnostics, microbiology, and parasitology. All RADIL employees will join IDEXX and continue operations in Columbia.

“The acquisition of RADIL represents a natural extension of our business strategy and aligns well with our overall corporate purpose – to create long-term value for our shareholders while enhancing the health and well-being of pets, people and livestock,” added Ayers.

IDEXX shares closed in positive territory for the fourth consecutive day of trading, closing at $73.19 to finish Monday trading.

Latest News

Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Lipocine  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Lipocine Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Atlanticus  Share Price
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Atlanticus Share Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Cancer Genetics  Share Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Cancer Genetics Share Price
iTicoin  Reaches Market Cap of $374,864.00
iTicoin Reaches Market Cap of $374,864.00
Zacks: Brokerages Anticipate Investar Holding Corp  Will Post Quarterly Sales of $14.84 Million
Zacks: Brokerages Anticipate Investar Holding Corp Will Post Quarterly Sales of $14.84 Million
Vascular Biogenics Ltd  Receives Consensus Recommendation of “Hold” from Analysts
Vascular Biogenics Ltd Receives Consensus Recommendation of “Hold” from Analysts


© 2006-2018 Ticker Report. Google+.